Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics
Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics
批准号:
9049453
负责人:
WILLIAM R ROUSH
金额:
$49.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2017-04-30
关键词:
AffinityAffinity ChromatographyAntineoplastic AgentsBiochemicalBiochemical GeneticsBiologicalBiological AssayBrainBreast Cancer CellCell LineCell physiologyCellsChemistryChronicCircadian RhythmsClinicColon CarcinomaCritical PathwaysCytoskeletonDNA DamageDerivation procedureDevelopmentDoseDrug KineticsFiberGenetic studyGlioblastomaGoalsGrantGrowthHealthHousingHumanIn VitroKnock-in MouseKnockout MiceLeadLegal patentLinkLungMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMass Spectrum AnalysisMelanoma CellMetastatic MelanomaModelingMolecular ModelsMusNeurodegenerative DisordersNormal CellOrganic ChemistryPenetrationPharmaceutical ChemistryPharmaceutical PreparationsPhosphorylationPhosphotransferasesPhysiologicalPre-Clinical ModelProcessPropertyProtein IsoformsProtein-Serine-Threonine KinasesRegulationRenal carcinomaReportingResearchResistanceRoleSafetySerineSignal TransductionSleep DisordersSpecificityTestingTherapeuticTherapeutic StudiesTumor-DerivedUnited States National Institutes of HealthXenograft ModelXenograft procedureanaloganti-cancer therapeuticbasecancer cellcancer geneticscasein kinasecasein kinase Ichemotherapyconventional therapydrug developmentdrug metabolismefficacy testinggenetic approachimprovedin vivoinhibitor/antagonistknock-downmalignant breast neoplasmmelanomamolecular modelingmouse modelmutantnanomolarneoplastic cellnovelnovel therapeuticsoverexpressionpre-clinicalpreclinical studyreceptorresponsesmall moleculesmall molecule inhibitortooltriple-negative invasive breast carcinomatumortumorigenic
中文摘要
描述(由申请人提供):我们研究团队的目标是优化和评估酪蛋白激酶1 (CK1δ/ ε) δ和ε亚型抑制剂的化合物。CK1δ/ ε是单体丝氨酸/苏氨酸蛋白激酶,可调节多种细胞过程,包括Wnt信号传导、DNA损伤反应和昼夜节律。CK1δ/ ε的异常调控与多种癌症、神经退行性疾病和睡眠障碍有关。重要的是,我们的研究团队结合了药物和合成有机化学的专业知识以及新疗法的衍生(PI Dr. William Roush),与癌症遗传学和临床前治疗研究(共同pi Dr. John Cleveland)以及药物开发和抗癌激酶治疗(共同pi Dr. Derek Duckett)的合作表明,我们新的内部高选择性和ATP竞争性CK1δ/ λ抑制剂具有非常低的纳摩尔生化和抗癌(黑色素瘤,乳腺癌和胶质母细胞瘤[GBM])细胞效力。此外,在黑色素瘤和三阴性乳腺癌细胞中的离体遗传研究表明,我们的化合物的抗肿瘤活性与抑制CK1δ/柱活性一致,原位异种移植试验表明,我们的CK1δ/柱抑制剂在体内具有有效的抗黑色素瘤和抗gbm活性。此外,NCI-60筛选和中空纤维测定表明,我们的CK1δ/柱抑制剂对包括结肠癌、肺癌和肾癌在内的其他人类癌症具有显著的效力。重要的是,我们的先导化合物通常没有毒性,因为这些CK1δ/ λ抑制剂不会损害某些肿瘤类型或正常细胞的生长或存活,并且在临床前研究中,它们在慢性21天BID剂量中具有良好的耐受性。因此,我们假设CK1δ/ λ亚型是开发癌症治疗方法的极具吸引力的靶点。在Aim 1中,我们的主要CK1δ/柱抑制剂的药物样特性(包括脑穿透性)将使用重复药物化学、DMPK和功效筛选进行优化。我们将使用严格的研究操作计划来优先考虑CK1δ/ λ抑制剂,这将流入目标2和3中概述的研究中。在Aim中,我们将使用一系列遗传学方法,严格测试我们的先导化合物和优化的类似物的抗癌活性是否仅仅是由于抑制CK1δ和/或ck1λ,或者其他生物学相关靶点是否有助于其效力。使用小鼠模型,我们还测试了CK1δ和/或ck1λ在突变brf驱动的黑色素瘤发展中的作用。最后,在Aim 3中,将使用小鼠和人类黑色素瘤、人类三阴性乳腺癌和原发性人类GBM的异种移植物作为单一药物或与常规疗法联合使用,测试顶级化合物的抗肿瘤功效。我们认为,我们的研究团队将产生一系列新的、有效的、安全的针对CK1δ/ λ的抗癌药物,这些药物将作为广谱治疗药物用于治疗许多耐药恶性肿瘤。
英文摘要
DESCRIPTION (provided by applicant): The goal of our research team is to optimize and evaluate compounds that are inhibitors of the delta and epsilon isoforms of casein kinase 1 (CK1δ/ϵ). CK1δ/ϵ are monomeric serine/threonine protein kinases that regulate diverse cellular processes including Wnt signaling, the DNA damage response and circadian rhythms. Aberrant regulation of CK1δ/ϵ is implicated in various cancers, and in neurodegenerative and sleep disorders. Importantly, our research team, which combines expertise in medicinal and synthetic organic chemistry and the derivation of novel therapeutics (PI Dr. William Roush), with those in cancer genetics and preclinical therapeutic studies (co-PI Dr. John Cleveland) and drug development and anti- cancer kinase therapeutics (co-PI Dr. Derek Duckett) has demonstrated that our new in-house and highly selective and ATP competitive CK1δ/ϵ inhibitors have very low nanomolar biochemical and anti-cancer (melanoma, breast cancer and glioblastoma [GBM]) cell potency. Furthermore, ex vivo genetic studies in melanoma and triple-negative breast cancer cells indicate that the anti-tumor activity of our compounds is consistent with inhibition of CK1δ/ϵ activity and pilot orthotopic xenograft studies have shown that our CK1δ/ϵ inhibitors have potent anti-melanoma and anti-GBM activity in vivo. In addition, NCI-60 screens and hollow fiber assays have shown that our CK1δ/ϵ inhibitors have remarkable potency against other human cancers that include colon, lung and renal cancer. Importantly, our lead compounds are not generally toxic, as these CK1δ/ϵ inhibitors do not compromise the growth or survival of some tumor types or of normal cells and they are well tolerated in chronic 21 day BID dosing in pre-clinical studies. Thus, we hypothesize that the CK1δ/ϵ isoforms are highly attractive targets for the development of cancer therapeutics. In Aim 1 the drug-like properties - including brain penetration - of our lead CK1δ/ϵ inhibitors will be optimized using reiterative medicinal chemistry, DMPK, and efficacy screens. We will use a rigorous research operating plan to prioritize CK1δ/ϵ inhibitors which will flow into studies outlined in Aims 2 and 3. In Aim , using a battery of genetic approaches, we will rigorously test whether the anti-cancer activity of our lead compounds and optimized analogs is solely due to inhibition of CK1δ and/or CK1ϵ, or whether other biologically relevant targets contribute to their potency. Using mouse models we also test the roles of CK1δ and/or CK1ϵ in the development of mutant BRaf-driven melanoma. Finally, in Aim 3, top compounds will be tested for their anti-tumor efficacy using xenografts of mouse and human melanoma, human triple negative breast cancer, and of primary human GBM both as single agents and in combination with conventional therapies. We submit that our research team will generate a cast of new, potent and safe anti-cancer agents targeting CK1δ/ϵ that will be useful as broad-spectrum therapeutics against a host of resistant malignancies.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics
-
批准号:8631767
-
项目类别:
-
资助金额:$48.43万
-
财政年份:2014
-
负责人:WILLIAM R ROUSH
-
依托单位:
Targeting Casein Kinase 1d/e (CK1d/1e) in Cancer Therapeutics
-
批准号:8840911
-
项目类别:
-
资助金额:$49.2万
-
财政年份:2014
-
负责人:WILLIAM R ROUSH
-
依托单位:
SAR Analysis/Med Chem (Florida)
-
批准号:8538725
-
项目类别:
-
资助金额:$94.88万
-
财政年份:2012
-
负责人:WILLIAM R ROUSH
-
依托单位:
SAR Analysis/Med Chem (Florida)
-
批准号:8120939
-
项目类别:
-
资助金额:$269.44万
-
财政年份:2010
-
负责人:WILLIAM R ROUSH
-
依托单位:
SAR Analysis/Med Chem (Florida)
-
批准号:8332835
-
项目类别:
-
资助金额:$320.02万
-
财政年份:2008
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHETIC CHEMISTRY
-
批准号:6816899
-
项目类别:
-
资助金额:$19.63万
-
财政年份:2004
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF INHIBITORS OF PARASITIC CYSTEINE PROTEASES
-
批准号:6338609
-
项目类别:
-
资助金额:$11.17万
-
财政年份:2000
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF INHIBITORS OF PARASITIC CYSTEINE PROTEASES
-
批准号:6099783
-
项目类别:
-
资助金额:$11.17万
-
财政年份:1999
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF CRUZAIN INHIBITORS
-
批准号:6268162
-
项目类别:
-
资助金额:$13.29万
-
财政年份:1998
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF CRUZAIN INHIBITORS
-
批准号:6235219
-
项目类别:
-
资助金额:$15.37万
-
财政年份:1997
-
负责人:WILLIAM R ROUSH
-
依托单位:
300 MHZ NMR SPECTROMETER UPGRADE
-
批准号:2286099
-
项目类别:
-
资助金额:$19.72万
-
财政年份:1995
-
负责人:WILLIAM R ROUSH
-
依托单位:
ACYCLIC DIASTEREOSELECTION: METHODOLOGY AND SYNTHESIS
-
批准号:6351182
-
项目类别:
-
资助金额:$23.15万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
ACYCLIC DIASTEREOSELECTION: METHODOLOGY AND SYNTHESIS
-
批准号:6498661
-
项目类别:
-
资助金额:$23.8万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
CHIRAL CROTYLBORONATIES; METHODOLOGY AND SYNTHESIS
-
批准号:3294875
-
项目类别:
-
资助金额:$14.59万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
ACYCLIC DIASTEREOSELECTION: METHODOLOGY AND SYNTHESIS
-
批准号:6628804
-
项目类别:
-
资助金额:$24.5万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF POLYHDROXYLATED NATURAL PRODUCTS
-
批准号:6684084
-
项目类别:
-
资助金额:$27.18万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
ACYCLIC DIASTEREOSELECTION--METHODOLOGY AND SYNTHESIS
-
批准号:2643506
-
项目类别:
-
资助金额:$12.71万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF OLIVOMYCIN A AND POLYHYDROXYLATED COMPOUNDS
-
批准号:2179607
-
项目类别:
-
资助金额:$21.15万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
CHIRAL CROTYLBORONATES--METHODOLOGY AND SYNTHESIS
-
批准号:2179335
-
项目类别:
-
资助金额:$19.35万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
SYNTHESIS OF OLIVOMYCIN A & POLYHYDROXYLATED COMPOUNDS
-
批准号:3295675
-
项目类别:
-
资助金额:$13.8万
-
财政年份:1988
-
负责人:WILLIAM R ROUSH
-
依托单位:
海外基金